A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature

Ragupathi, Loheetha; Najfeld, Vesna; Chari, Ajai; Petersen, Bruce; Jagannath, Sundar; Mascarenhas, John

doi:10.1016/j.clml.2012.09.010

Cited by 17 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In more recent articles, fifteen cases reported to have multiple myeloma and CML were reviewed. Six of these cases revealed the presence of the Philadelphia translocation at the time of diagnosis with multiple myeloma, further supporting a common pluripotent stem cell [ 1 – 7 ]. Moreover, examination of the bone marrow showed a 19% population of myeloma cells and an overall 97% positivity for BCR-ABL fusion signal, indicating that some of the myeloma cells were positive for BCR-ABL rearrangement [ 1 , 2 ].…”

Section: Discussionmentioning

confidence: 96%

“…Another potential theory of multiple simultaneous malignancies includes the sharing of a common malignant pluripotent progenitor stem cell which may allow further transformation of both lymphoid and myeloid differentiations. It has been proposed that plasma cell myeloma and CML may evolve from the same hematopoietic stem cell [ 1 , 8 , 12 ]. There have been multiple accounts in which plasma cell neoplasms, including plasma cell leukemia and multiple myeloma, have been seen in coexistence with or arising in the background of CML [ 37 – 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…This reveals the capability of CML in differentiating into either myeloid lineage or lymphoid lineage. Furthermore, the Philadelphia chromosome (Ph) has been linked to increased cell survival, proliferation, and malignant transformation [ 1 , 40 ] and has been found in all hematopoietic cell lineages including erythropoietic cells, megakaryocytes, macrophages, and B-lymphocytes [ 1 , 12 , 41 ]. An article highlights 4 cases of multiple myeloma in particular where the Philadelphia chromosome has been identified, providing the potential discovery of a common genetic abnormality among plasma cell neoplasms and CML [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…Plasma cell myeloma, a hematologic neoplasm of lymphoid origin, has an incidence of 4.5 cases per 100,000 person annually in the United States while Chronic Myelogenous Leukemia, a neoplasm of myeloid origin, has an incidence of 1-2 cases per 100,000 person annually worldwide. As coexisting hematologic neoplasms in general are a rare entity, there are only a limited number of case reports with both multiple myeloma and CML [ 1 – 13 ]. Literature review shows case reports of new hematopathologic neoplasms occurring after treatment of an initial hematologic malignancy; this can be a single additional neoplasm or up to three new neoplasms after treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Maerki

Katava

Siegel

et al. 2014

Case Reports in Hematology

View full text Add to dashboard Cite

Background. Multiple articles discuss the rare incidence and potential causes of second hematologic disorders arising after treatment of Chronic Myelogenous Leukemia (CML), leading to the theory of imatinib, the current treatment regimen for CML, as a possible trigger for the development of secondary neoplasms. Our case eliminates the possibility of imatinib as the sole cause since our patient received a diagnosis of simultaneous plasma cell myeloma, CML, and a Jak2 mutation positive myeloproliferative disorder (MPD) arising de novo, prior to any treatment. We will further investigate into alternative theories as potential causes for multiple hematopathologic disorders. Case Report. There are currently no reported cases with the diagnosis of simultaneous plasma cell myeloma, chronic myelogenous leukemia, and Jak2 positive myeloproliferative disorder. We present a case of a 77-year-old male who was discovered to have these three concurring hematopathologic diagnoses. Our review of the literature includes a look at potential associations linking the three coexisting hematologic entities. Conclusion. The mechanism resulting in simultaneous malignancies is most likely multifactorial and potentially includes factors specific to the host, continuous stimulation of the immune system, previous chemotherapy or radiation, a potential common pluripotent stem cell, or, lastly, preexisting myeloma which may increase the susceptibility of additional malignancies.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Maerki

Katava

Siegel

et al. 2014

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…[6] and Ragupathi et al [7] both reported CML developing almost 2 years following the initial diagnosis of IgGκ MM in elderly individuals.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

AlShehry¹,

Al-Huneini²,

Lipton³

et al. 2015

Acta Haematol

View full text Add to dashboard Cite

Lymphoproliferative disorders presenting simultaneously with or subsequent to the occurrence of chronic myeloid leukemia (CML) have rarely been reported. Herein, we report 8 cases of a variety of lymphoproliferative conditions associated with CML at different times during the course of the disease. All 8 patients were treated with tyrosine kinase inhibitors at some point during the course of their illness. The literature regarding the uncommon association of these apparently unrelated disorders is reviewed as well as the possible underlying mechanisms that could be associated with this phenomenon.

show abstract

Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

Macauda

Giaccherini

Sáinz

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) are a group of diseases that cause myeloid hematopoietic cells to overproliferate. Epidemiological and familial studies suggest that genetic factors contribute to the risk of developing MPN, but the genetic susceptibility of MPN is still not well known. Indeed, only few loci are known to have a clear role in the predisposition to this disease. Some studies reported a diagnosis of MPNs and multiple myeloma (MM) in the same patients, but the biological causes are still unclear. We tested the hypothesis that the two diseases share at least partly the same genetic risk loci. In the context of a European multicenter study with 460 cases and 880 controls, we analyzed the effect of the known MM risk loci, individually and in a polygenic risk score (PRS). The most significant result was obtained among patients with chronic myeloid leukemia (CML) for PS0RS1C1‐rs2285803, which showed to be associated with an increased risk (OR = 3.28, 95% CI 1.79‐6.02, P = .00012, P = .00276 when taking into account multiple testing). Additionally, the PRS showed an association with MPN risk when comparing the last with the first quartile of the PRS (OR = 2.39, 95% CI 1.64‐3.48, P = 5.98 × 10−6). In conclusion, our results suggest a potential common genetic background between MPN and MM, which needs to be further investigated.

show abstract

A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature

Cited by 17 publications

References 27 publications

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder

Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series

Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?

Contact Info

Product

Resources

About